NeoGenomics, Inc. increased the size of its Board of Directors from nine to ten members. Carolyn S. Starrett was appointed as an independent director, effective June 23, 2026. Ms. Starrett will serve until the 2027 annual meeting of stockholders. The appointment aims to leverage Ms. Starrett's expertise in AI, real-world data, and oncology-focused technology.